Display options
Cite
Masarova L, Yin CC, Cortes JE, et al. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017;6:30doi: 10.1186/s40164-017-0090-5.
Masarova, L., Yin, C. C., Cortes, J. E., Konopleva, M., Borthakur, G., Newberry, K. J., Kantarjian, H. M., Bueso-Ramos, C. E., & Verstovsek, S. (2017). Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Experimental hematology & oncology, 630. https://doi.org/10.1186/s40164-017-0090-5
Masarova, Lucia, et al. "Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)." Experimental hematology & oncology vol. 6 (2017): 30. doi: https://doi.org/10.1186/s40164-017-0090-5
Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017 Nov 09;6:30. doi: 10.1186/s40164-017-0090-5. eCollection 2017. PMID: 29152412; PMCID: PMC5679503.
Copy Download .nbib Format: NLM
Share it on

Exp Hematol Oncol. 2017 Nov 09;6:30. doi: 10.1186/s40164-017-0090-5. eCollection 2017.

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Experimental hematology & oncology

Lucia Masarova, C Cameron Yin, Jorge E Cortes, Marina Konopleva, Gautam Borthakur, Kate J Newberry, Hagop M Kantarjian, Carlos E Bueso-Ramos, Srdan Verstovsek

Affiliations

  1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 428, Houston, TX 77030 USA.
  2. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.

PMID: 29152412 PMCID: PMC5679503 DOI: 10.1186/s40164-017-0090-5

Abstract

BACKGROUND: Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET) and polycythemia vera (PV). We recently reported results of a phase 2 trial of PEG-IFN-α-2a in 83 patients with ET and PV after a median follow-up of 83 months. Here we report an analysis of bone marrow (BM) responses in these patients.

METHODS: Among 83 patients, 58 (70%, PV 25, ET 31) had evaluable BM samples. BM responses and fibrosis grading were defined according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment, and the European Consensus on grading of BM fibrosis, respectively. BM was assessed prior to enrollment, and every 6-24 months while on therapy in all patients, and after therapy discontinuation in some patients.

RESULTS: The median age of analyzed 58 patients was 52 years, and 29% were males. After a median follow-up of 84 months, 32 patients are still on study. Hematologic (HR) and molecular responses (MR) were seen in 93 and 69% patients, respectively. Twenty-nine patients (50%) had a BM response, including 13 (22%) with a complete BM response (BM-CR). Moreover, 13 patients (22%) have experienced complete resolution of bone marrow reticulin fibrosis. Patients with BM response had higher duration of HR and MR, and lower discontinuation rate. Furthermore, patients with BM-CR had a higher probability of complete MR. The median duration of BM-CR was 30 months, and 9 patients have maintained their BM-CR (69%), including five who have maintained their response after discontinuation of therapy. Despite this observation, the pattern of HR, MR and BM response, their durability and interrelation was heterogeneous.

CONCLUSIONS: Our results show the ability of PEG-IFN-α-2a to induce complete BM responses in a subset of ET and PV patients, but its correlation with durable clinically relevant treatment benefit warrants further investigation.

Keywords: Essential thrombocythemia; Histomorphological response; Pegylated interferon alfa-2a; Polycythemia vera

References

  1. Hematology. 2009 Dec;14 (6):331-4 - PubMed
  2. Blood Cancer J. 2017 Mar 10;7(3):e538 - PubMed
  3. Mayo Clin Proc. 2006 Feb;81(2):159-66 - PubMed
  4. Ann Hematol. 2008 Oct;87(10 ):847-50 - PubMed
  5. Lancet. 1988 Aug 13;2(8607):403 - PubMed
  6. Nature. 2009 Apr 16;458(7240):904-8 - PubMed
  7. Semin Hematol. 1997 Jan;34(1):17-23 - PubMed
  8. Blood. 2012 Mar 8;119(10):2239-41 - PubMed
  9. Blood. 2011 Jun 16;117(24):6669-72 - PubMed
  10. Mod Pathol. 2015 Oct;28(10):1315-23 - PubMed
  11. Blood. 2016 May 19;127(20):2391-405 - PubMed
  12. Eur J Haematol. 2011 Feb;86(2):148-55 - PubMed
  13. Haematologica. 2005 Aug;90(8):1128-32 - PubMed
  14. Blood. 2013 Jun 6;121(23):4778-81 - PubMed
  15. Haematologica. 2017 Mar;102(3):e97-e99 - PubMed
  16. Br J Haematol. 1990 Jan;74(1):10-6 - PubMed
  17. Blood. 2008 Oct 15;112(8):3065-72 - PubMed
  18. J Clin Oncol. 2009 Jun 20;27(18):2991-9 - PubMed
  19. Blood. 2013 Aug 8;122(6):893-901 - PubMed
  20. J Clin Oncol. 2009 Nov 10;27(32):5418-24 - PubMed
  21. Lancet Haematol. 2017 Apr;4(4):e165-e175 - PubMed
  22. Leukemia. 2008 Nov;22(11):1990-8 - PubMed
  23. J Clin Oncol. 2005 Apr 1;23(10):2224-32 - PubMed
  24. Cancer Genet. 2013 Apr;206(4):116-23 - PubMed
  25. Leuk Lymphoma. 2015 Jun 18;:1-7 - PubMed
  26. Curr Drug Targets. 2011 Mar 1;12(3):392-419 - PubMed

Publication Types

Grant support